BioCentury
ARTICLE | Clinical News

ALKS 4230: Phase I started

June 20, 2016 7:00 AM UTC

Alkermes began a dose-escalation, dose-expansion Phase I trial to evaluate IV ALKS 4230 in patients who are refractory or intolerant to established therapies. ...